Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2018902

O=C(NC1CC1)C1CCCNC1.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.50
TSHR P16473 2/20 0.50
SLC6A11 P48066 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SLC6A13 Q9NSD5 1/20 0.50
CYP2D6 P10635 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
ATM Q13315 1/20 0.45
POLB P06746 1/20 0.45
TNKS O95271 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38
NOS2 P35228 1/20 0.38
ROCK2 O75116 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
ULK1 O75385 1/20 0.35
CPN1 P15169 1/20 0.35
CPB2 Q96IY4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL610386 0.94 SLC6A1 (0.47) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
Trifluoroacetic Acid SCHEMBL1609525 0.91 POLB (0.51) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL6321055 0.89 SLC6A1 (0.57) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL2328415 0.89 SLC6A1 (0.57) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL19278876 0.89 SLC6A1 (0.57) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
Trifluoroacetic Acid SCHEMBL2146176 0.88 POLB (0.49) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL24322676 0.84 SMN1; SMN2 (0.55) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL29542501 0.84 SMN1; SMN2 (0.55) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL612704 0.83 SLC6A1 (0.50) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL22642315 0.82 POLB (0.67) SLC6A1TSHRSLC6A11LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160180-A1 Cannabinoid Receptor Ligands ASTRAZENECA AB (SE) 2011-06-30 US disclosed
CN-101827838-A Cannabinoid receptor ligand ASTRAZENECA AB 2010-09-08 CN disclosed
EP-2190838-A1 CANNABINOID RECEPTOR LIGANDS AstraZeneca AB (SE) 2010-06-02 EP disclosed
US-20090062251-A1 Novel Compounds 002 ASTRAZENECA AB (SE) 2009-03-05 US disclosed
WO-2009024819-A1 CANNABINOID RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062251-A1 Novel Compounds 002 OPRL1, OPRK1, OPRM1 SLC6A1 807/4885TSHR 2124/4885SLC6A11 697/4885
US-20110160180-A1 Cannabinoid Receptor Ligands CNR1, CNR2, OPRL1 SLC6A1 757/4885TSHR 392/4885SLC6A11 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.